Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance
June 27, 2024 08:00 ET
|
Allarity Therapeutics, Inc.
Boston (June 27, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer...
Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
June 25, 2024 08:00 ET
|
Allarity Therapeutics, Inc.
Multiple patients have now exceeded 30 weeks on treatment Boston (June 25, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical...
Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
May 20, 2024 08:00 ET
|
Allarity Therapeutics, Inc.
Boston (May 20, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments,...
Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances
May 14, 2024 16:01 ET
|
Allarity Therapeutics, Inc.
- Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved - On Track to Regain Compliance with All Nasdaq Listing Requirements - No Variable Priced Securities are...
Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
May 07, 2024 09:30 ET
|
Allarity Therapeutics, Inc.
- Conversions Eliminate All Variable Priced Derivative Securities - Conversions Eliminate Any Market Overhang from Warrants - Series A Preferred and Warrant Conversions were Investor Initiated -...
Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1
May 06, 2024 08:00 ET
|
Allarity Therapeutics, Inc.
- Stockholders’ equity significantly surpasses the $2.5 million minimum required by Nasdaq - Company is to seek Nasdaq’s formal confirmation of compliance with equity requirements under the...
Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
May 02, 2024 08:00 ET
|
Allarity Therapeutics, Inc.
Boston (May 2, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today...
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
April 29, 2024 07:00 ET
|
Allarity Therapeutics, Inc.
Boston (April 29, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments,...
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)
April 17, 2024 09:10 ET
|
Allarity Therapeutics, Inc.
Boston (April 17, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today...
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
April 04, 2024 09:15 ET
|
Allarity Therapeutics, Inc.
Boston (April 4, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today...